AR042046A1 - Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos - Google Patents
Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenosInfo
- Publication number
- AR042046A1 AR042046A1 ARP030104210A ARP030104210A AR042046A1 AR 042046 A1 AR042046 A1 AR 042046A1 AR P030104210 A ARP030104210 A AR P030104210A AR P030104210 A ARP030104210 A AR P030104210A AR 042046 A1 AR042046 A1 AR 042046A1
- Authority
- AR
- Argentina
- Prior art keywords
- aryl
- heteroaryl
- heteroaralkyl
- aralkyl
- alkyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 101710088194 Dehydrogenase Proteins 0.000 title 1
- 239000003098 androgen Substances 0.000 title 1
- 229940030486 androgens Drugs 0.000 title 1
- 125000003118 aryl group Chemical group 0.000 abstract 11
- 125000001072 heteroaryl group Chemical group 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 8
- 125000004475 heteroaralkyl group Chemical group 0.000 abstract 8
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 abstract 3
- 101100516568 Caenorhabditis elegans nhr-7 gene Proteins 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 3
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 3
- 102000054917 17-beta-hydroxysteroid dehydrogenase type 3 Human genes 0.000 abstract 2
- 108010084625 17-beta-hydroxysteroid dehydrogenase type 3 Proteins 0.000 abstract 2
- -1 methylenedioxy Chemical group 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 230000006872 improvement Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/28—Antiandrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Inhibidores de 17beta-hidroxiesteroide deshidrogenasa de tipo 3, métodos para preparar dichos compuestos, composiciones farmacéuticas que contienen uno o más de dichos compuestos, métodos de preparación de formulaciones farmacéuticas que comprende uno o más de dichos compuestos, y métodos de tratamiento , prevención, inhibición o mejoramiento de una o más enfermedades asociadas con 17beta-hidroxiesteroide deshidrogenasa de tipo 3, usando dichos compuestos o composiciones farmacéuticas. Reivindicación 1: Un compuesto representado por la fórmula estructural (1), en la cual: X es CH o N; Z es O o N(R6); R1 y R2 son iguales o diferentes, estando cada uno de ellos independientemente seleccionado del grupo que consiste en arilo, heteroarilo, aralquilo y heteroaralquilo, donde cada uno de dichos arilo, heteroarilo, aralquilo y heteroaralquilo pueden estar no sustituidos o pueden estar opcionalmente independientemente sustituidos con una o más porciones que pueden ser iguales o diferentes, estando cada uno de las porciones independientemente seleccionados del grupo que consiste en halógeno, alquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, cicloalquilo, heterociclilo, CF3, CN, -OCF3, -OR6, -C(O)R7, -NR6R7, -C(O)OR6, -C(O)NR6R7, -SR6, -S(O2)R7, -S(O2)NR6R7, -N(R6)S(O2)R7, -N(R6)C(O)R7 y -N(R6)C(O)NR6R7; R3 es H o -OR6, con la condición de que cuando X es N, R3 no es -OR6; R4 está seleccionado del grupo que consiste en H, alquilo, arilo, cicloalquilo, aralquilo, heteroarilo, heteroaralquilo, y heterociclilo, m es un número de 0 a 4, y cuando m es más de 1, los grupos R4 pueden ser iguales o diferentes y están independientemente seleccionados; R5 es -C(O)R7 o -S(O2)R7; R6 está seleccionado del grupo que consiste en H, alquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, cicloalquilo y heterociclilo, donde cada uno de dichos alquilo, arilo, heteroarilo, aralquilo, heteroaralquilo, cicloalquilo y heterociclilo, pueden estar no sustituidos o pueden estar opcionalmente independientemente sustituidos con una o más porciones que pueden ser iguales o diferentes, donde cada porción está independientemente seleccionados del grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, CF3, OCF3, CN, -OR7, -NHR7, -N(R7)2, -CH2OR7, -C(O)R7, -C(O)OR7, -C(O)NHR7, -C(O)N(R7)2, -SR7, -S(O2)R7, -S(O2)NHR7, -S(O2)N(R7)2, -N(R7)S(O2)R7, -N(R7)C(O)R7, -N(R7)C(O)NHR7 y -N(R7)C(O)N(R7)2; y R7 está seleccionado del grupo que consiste en alquilo, arilo, heteroarilo, aralquilo,. Heteroaralquilo, -OR6, -NHR6, y -N(R6)2, donde cada uno de dichos alquilo, heteroaralquilo, arilo, heteroarilo, y aralquilo pueden estar no sustituidos y puede estar opcionalmente sustituidos con una o más porciones que pueden ser iguales o diferentes, estando cada porción independientemente seleccionada del grupo que consiste en halógeno, alquilo, arilo, cicloalquilo, CF3, OCF3, CN, -OR6, -NHR6, -N(R6)2, -CH2OR6, -C(O)OR6, -C(O)NHR6, -C(O)N(R6)2, -SR6, -S(O2)R6, -S(O2)NHR6, -S(O2)N(R6)2, -N(R6)S(O2)R6, -N(R6)C(O)R6, -N(R7)C(O)NHR6 y -N(R7)C(O)N(R7)2, en el cual los dos grupos R6 o los dos grupos R7 en las porciones -N(R6)2 y -(N(R7)2, pueden ser respectivamente iguales o diferentes y estar independientemente seleccionados, en los cuales además los sustituyentes cualquiera adyacentes en un arilo o heteroarilo pueden estar unidos conjuntamente para formar un grupo metilendioxi o etilendioxi.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42726302P | 2002-11-18 | 2002-11-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR042046A1 true AR042046A1 (es) | 2005-06-08 |
Family
ID=32326512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104210A AR042046A1 (es) | 2002-11-18 | 2003-11-14 | Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US7074795B2 (es) |
| EP (1) | EP1562901B1 (es) |
| JP (2) | JP4614770B2 (es) |
| CN (1) | CN100374421C (es) |
| AR (1) | AR042046A1 (es) |
| AT (1) | ATE469886T1 (es) |
| AU (1) | AU2003290799A1 (es) |
| CA (1) | CA2506290C (es) |
| CL (1) | CL2003002356A1 (es) |
| DE (1) | DE60332862D1 (es) |
| ES (1) | ES2345146T3 (es) |
| MX (1) | MXPA05005360A (es) |
| MY (1) | MY130792A (es) |
| PE (1) | PE20040750A1 (es) |
| TW (1) | TW200412964A (es) |
| WO (1) | WO2004046111A1 (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60323765D1 (de) | 2002-12-17 | 2008-11-06 | Schering Corp | Inhibitoren der 17 beta-hydroxysteroiddehydrogenase des typs 3 zur behandlung androgenabhängiger krankheiten |
| GB0513702D0 (en) | 2005-07-04 | 2005-08-10 | Sterix Ltd | Compound |
| CA2606004A1 (en) * | 2005-08-02 | 2007-02-08 | Neurogen Corporation | Dipiperazinyl ketones and related analogues |
| US8080540B2 (en) | 2006-09-19 | 2011-12-20 | Abbott Products Gmbh | Therapeutically active triazoles and their use |
| US8288367B2 (en) | 2006-11-30 | 2012-10-16 | Solvay Pharmaceuticals Gmbh | Substituted estratriene derivatives as 17BETA HSD inhibitors |
| US8501940B2 (en) * | 2008-07-15 | 2013-08-06 | Hoffmann-La Roche Inc. | Tetrahydrocinnoline derivatives |
| PL2702982T3 (pl) * | 2011-04-25 | 2017-07-31 | Jun-Hyoung Park | Kompozycja do miejscowego stosowania do zapobiegania wypadaniu włosów i stymulowania porostu włosów |
| AU2014300894A1 (en) | 2013-06-25 | 2016-01-28 | Forendo Pharma Ltd | Therapeutically active 17-nitrogen substituted estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxysteroid dehydrogenase |
| US10377791B2 (en) | 2013-06-25 | 2019-08-13 | Forendo Pharma Ltd. | Therapeutically active estratrienthiazole derivatives as inhibitors of 17 B-hydroxysteroid dehydrogenase, type 1 |
| WO2014207311A1 (en) | 2013-06-25 | 2014-12-31 | Forendo Pharma Ltd | Therapeutically active estratrienthiazole derivatives as inhibitors of 17.beta.-hydroxy-steroid dehydrogenase, type 1 |
| CN107207561B (zh) | 2014-12-23 | 2020-03-31 | 佛恩多制药有限公司 | 17β-HSD1–抑制剂的前药 |
| EP3237430B1 (en) | 2014-12-23 | 2019-03-20 | Forendo Pharma Ltd | PRODRUGS OF 17ß -HSD1 -INHIBITORS |
| UY36875A (es) | 2015-09-02 | 2017-03-31 | Glaxosmithkline Intellectual Property (No 2) Ltd | Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades |
| AU2018279205B2 (en) | 2017-06-08 | 2021-04-15 | Forendo Pharma Ltd | 15.beta.-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
| IL275337B2 (en) | 2017-12-15 | 2024-06-01 | Inthera Bioscience AG | 1-(piperidinocarbonylmethyl)-2-oxopyrazine derivatives for cancer therapy |
| US20220041647A1 (en) | 2018-12-05 | 2022-02-10 | Forendo Pharma Ltd | Estra-1,3,5(10)-triene compounds condensed in position 16(17) with a pyrazole ring as inhibitors of 17-hsd1 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3590389T1 (de) | 1984-08-02 | 1986-08-28 | Schering Corp., Kenilworth, N.J. | Pharmazeutische Zusammensetzung für eine Kombinationstherapie hormon-abhängiger Cancer |
| ES2077675T3 (es) | 1989-03-10 | 1995-12-01 | Endorecherche Inc | Terapia combinada para el tratamiento de enfermedades sensibles a los estrogenos. |
| ES2222633T3 (es) | 1989-07-07 | 2005-02-01 | Endorecherche Inc. | Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna. |
| DE69034035T2 (de) | 1989-07-07 | 2004-01-22 | Endorecherche Inc., Ste-Foy | Methode zur behandlung androgenbedingter krankheiten |
| US6060503A (en) | 1991-12-02 | 2000-05-09 | Endorecherche, Inc. | Benzopyran-containing compounds and method for their use |
| EP0650495B1 (en) | 1993-05-17 | 2000-11-08 | Endorecherche Inc. | Improved antiandrogens |
| US6124115A (en) | 1995-09-22 | 2000-09-26 | Endorecherche Inc. | Production and use of isolated type 5 17β-hydroxysteroid dehydrogenase |
| WO1998011092A1 (en) * | 1996-09-13 | 1998-03-19 | Schering Corporation | Tricyclic antitumor compounds being farnesyl protein transferase inhibitors |
| BR9908592A (pt) * | 1998-03-11 | 2001-04-24 | Endorech Inc | Processo para inibir a atividade de 17ß-hidroxiesteróide desidrogenase tipo 5, composição farmacêutica, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 5, processo para inibir 17ß-hidroxiesteróide desidrogenase tipo 3, inibidor de 17ß-hidroxiesteróide desidrogenase tipo 3, processos para tratar, ou reduzir o risco de desenvolver, câncer da próstata, hiperplasia prostática benigna, acne, seborréia, hirsutismo ou alopécia androgênica, sìndrome de ovário policìstico, câncer de mama, endometriose ou leiomioma, para inibir as secreções hormonais testiculares, para tratar puberdade precoce, e, kit |
| EP1423381B1 (en) * | 2001-09-06 | 2007-01-03 | Schering Corporation | 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| JP4309761B2 (ja) * | 2001-10-17 | 2009-08-05 | シェーリング コーポレイション | アンドロゲン依存性疾患の治療を目的とする１７βヒドロキシステロイドデヒドロゲナーゼ３型の阻害剤としてのピペリジンアセトアミンおよびピペラジンアセトアミン |
-
2003
- 2003-11-14 AT AT03783382T patent/ATE469886T1/de not_active IP Right Cessation
- 2003-11-14 MX MXPA05005360A patent/MXPA05005360A/es active IP Right Grant
- 2003-11-14 MY MYPI20034363A patent/MY130792A/en unknown
- 2003-11-14 CN CNB2003801086673A patent/CN100374421C/zh not_active Expired - Fee Related
- 2003-11-14 US US10/713,828 patent/US7074795B2/en not_active Expired - Fee Related
- 2003-11-14 TW TW092131992A patent/TW200412964A/zh unknown
- 2003-11-14 CA CA2506290A patent/CA2506290C/en not_active Expired - Fee Related
- 2003-11-14 JP JP2004553612A patent/JP4614770B2/ja not_active Expired - Fee Related
- 2003-11-14 ES ES03783382T patent/ES2345146T3/es not_active Expired - Lifetime
- 2003-11-14 AU AU2003290799A patent/AU2003290799A1/en not_active Abandoned
- 2003-11-14 EP EP03783382A patent/EP1562901B1/en not_active Expired - Lifetime
- 2003-11-14 AR ARP030104210A patent/AR042046A1/es unknown
- 2003-11-14 PE PE2003001156A patent/PE20040750A1/es not_active Application Discontinuation
- 2003-11-14 WO PCT/US2003/036203 patent/WO2004046111A1/en not_active Ceased
- 2003-11-14 CL CL200302356A patent/CL2003002356A1/es unknown
- 2003-11-14 DE DE60332862T patent/DE60332862D1/de not_active Expired - Lifetime
-
2006
- 2006-02-24 US US11/362,217 patent/US7476681B2/en not_active Expired - Fee Related
-
2010
- 2010-03-15 JP JP2010058356A patent/JP2010138204A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CL2003002356A1 (es) | 2005-02-11 |
| CA2506290C (en) | 2012-04-24 |
| MXPA05005360A (es) | 2005-08-03 |
| CA2506290A1 (en) | 2004-06-03 |
| TW200412964A (en) | 2004-08-01 |
| JP4614770B2 (ja) | 2011-01-19 |
| WO2004046111A1 (en) | 2004-06-03 |
| CN100374421C (zh) | 2008-03-12 |
| EP1562901A1 (en) | 2005-08-17 |
| US7476681B2 (en) | 2009-01-13 |
| US20040127503A1 (en) | 2004-07-01 |
| MY130792A (en) | 2007-07-31 |
| ES2345146T3 (es) | 2010-09-16 |
| ATE469886T1 (de) | 2010-06-15 |
| PE20040750A1 (es) | 2004-11-06 |
| AU2003290799A1 (en) | 2004-06-15 |
| US20060148816A1 (en) | 2006-07-06 |
| JP2010138204A (ja) | 2010-06-24 |
| HK1073313A1 (en) | 2005-09-30 |
| CN1738800A (zh) | 2006-02-22 |
| DE60332862D1 (de) | 2010-07-15 |
| EP1562901B1 (en) | 2010-06-02 |
| US7074795B2 (en) | 2006-07-11 |
| JP2006513169A (ja) | 2006-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR042046A1 (es) | Inhibidores de 17 beta-hidroxiesteroide deshidrogenasa de tipo 3 para el tratamiento de enfermedades que dependen de androgenos | |
| CO2021003298A2 (es) | Compuestos de sulfonamidaurea novedosos | |
| AR041724A1 (es) | Compuestos derivados de fenetanolamina y su utilizacion en composiciones farmaceuticas | |
| CO5631431A2 (es) | Indoles sustituidos novedosos | |
| PE20190705A1 (es) | COMPUESTOS DE BENZO[b] TIOFENO COMO AGONISTAS DE STING | |
| AR048820A1 (es) | Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3) | |
| CO5290256A1 (es) | Derivados pirazol triciclicos | |
| AR029150A1 (es) | Un derivado de piperidina, su empleo, un procedimiento para prepararlo y una composicin farmaceutica que lo comprende. | |
| CO5580815A2 (es) | Derivados de adamantana, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
| DE69833036D1 (de) | Sulfonylderivate | |
| ES2112929T3 (es) | Derivados de acido hidroxamico y composiciones farmaceuticas de ellos. | |
| CO5601020A2 (es) | Compuestos ox-azabiciclicos | |
| CY1110216T1 (el) | Παραγωγα αρυλαλκυλκαρβαμικων, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη αγωγη | |
| AR012032A1 (es) | Compuestos derivados 3'-n-oxido, 3'-n-dimetilamina, 9-oxima eritromicina a y un proceso para su preparacion | |
| AR061438A1 (es) | Derivados de entacapone | |
| AR044177A1 (es) | Proceso para la preparacion de trans-isomeros de derivados de la difenilazetidinona | |
| ATE460394T1 (de) | 5-asa-derivate mit entzündungshemmender und antibiotischer wirkung und verfahren zur behandlung von krankheiten mit diesen derivaten | |
| PE20210183A1 (es) | Tiofenocarboxamidas sustituidas y analogos de las mismas | |
| ES2101026T3 (es) | Derivados sulfatados de glicosaminoglicanoides. | |
| AR112900A1 (es) | Compuesto derivado de pirazol y uso de este | |
| PE20220252A1 (es) | Compuestos de pirrol | |
| EA202092858A1 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[1,2-b]ПИРИДАЗИНА | |
| AR071587A1 (es) | Compuestos heterociclicos como inhibidores de mek | |
| ES2079449T3 (es) | 1-aril-1-hidroxi-1-sustituido-3-(4-sustituido-1-piperazinil)-2-propanonas y su utilizacion en el tratamiento de los trastornos neurogenicos de la vejiga. | |
| ES2106185T3 (es) | 3-carboxiesteroides 17-beta-sustituidos no saturados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |